Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,040 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.
Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R, Coleman R, Borley A, Schmidt M, Rautenberg B, Kunze CA, Rhein U, Mehta K, Mousa K, Dibble T, Lu XL, von Minckwitz G, Bliss JM; Randomized European Celecoxib Trial (REACT) Trial Management Group and Investigators. Coombes RC, et al. Among authors: hicks j. JAMA Oncol. 2021 Sep 1;7(9):1291-1301. doi: 10.1001/jamaoncol.2021.2193. JAMA Oncol. 2021. PMID: 34264305 Free PMC article. Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).
Lee SM, Falzon M, Blackhall F, Spicer J, Nicolson M, Chaudhuri A, Middleton G, Ahmed S, Hicks J, Crosse B, Napier M, Singer JM, Ferry D, Lewanski C, Forster M, Rolls SA, Capitanio A, Rudd R, Iles N, Ngai Y, Gandy M, Lillywhite R, Hackshaw A. Lee SM, et al. Among authors: hicks j. J Clin Oncol. 2017 Feb;35(4):402-411. doi: 10.1200/JCO.2016.68.1841. Epub 2016 Nov 28. J Clin Oncol. 2017. PMID: 27893326 Free article. Clinical Trial.
IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer.
Landau DB, Hughes L, Baker A, Bates AT, Bayne MC, Counsell N, Garcia-Alonso A, Harden SV, Hicks JD, Hughes SR, Illsley MC, Khan I, Laurence V, Malik Z, Mayles H, Mayles WPM, Miles E, Mohammed N, Ngai Y, Parsons E, Spicer J, Wells P, Wilkinson D, Fenwick JD. Landau DB, et al. Among authors: hicks jd. Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1367-1377. doi: 10.1016/j.ijrobp.2016.03.031. Epub 2016 Mar 28. Int J Radiat Oncol Biol Phys. 2016. PMID: 27296040 Free PMC article. Clinical Trial.
Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer.
Punjabi A, Barrett E, Cheng A, Mulla A, Walls G, Johnston D, McAleese J, Moore K, Hicks J, Blyth K, Denholm M, Magee L, Gilligan D, Silverman S, Qureshi M, Clinch H, Hatton M, Philipps L, Brown S, O'Brien M, McDonald F, Faivre-Finn C, Hiley C, Evison M. Punjabi A, et al. Among authors: hicks j. Clin Oncol (R Coll Radiol). 2021 Aug;33(8):e331-e338. doi: 10.1016/j.clon.2021.03.019. Clin Oncol (R Coll Radiol). 2021. PMID: 33863615
Predicting the Risk of Disease Recurrence and Death Following Curative-intent Radiotherapy for Non-small Cell Lung Cancer: The Development and Validation of Two Scoring Systems From a Large Multicentre UK Cohort.
Evison M, Barrett E, Cheng A, Mulla A, Walls G, Johnston D, McAleese J, Moore K, Hicks J, Blyth K, Denholm M, Magee L, Gilligan D, Silverman S, Hiley C, Qureshi M, Clinch H, Hatton M, Philipps L, Brown S, O'Brien M, McDonald F, Faivre-Finn C. Evison M, et al. Among authors: hicks j. Clin Oncol (R Coll Radiol). 2021 Mar;33(3):145-154. doi: 10.1016/j.clon.2020.09.001. Epub 2020 Sep 23. Clin Oncol (R Coll Radiol). 2021. PMID: 32978027
Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions.
Rulach R, McLoone P, Lumsden G, McKay S, MacLaren V, Macphee J, Moore K, Omand M, Sproule M, Currie S, Aitken A, Ferguson R, Valentine R, Houston P, Harrow S, Hicks J. Rulach R, et al. Among authors: hicks j. Clin Oncol (R Coll Radiol). 2020 Apr;32(4):250-258. doi: 10.1016/j.clon.2019.09.055. Epub 2019 Oct 10. Clin Oncol (R Coll Radiol). 2020. PMID: 31607611
Hypofractionated Accelerated Concurrent Chemoradiotherapy in Inoperable Stage III Non-small Cell Lung Cancer: SOCCAR. A Large Single-Centre Experience.
Patibandla A, Featherstone C, Maclaren V, Lumsden G, Harrow S, Jones R, Chalmers AJ, McLoone P, Hicks J. Patibandla A, et al. Among authors: hicks j. Clin Oncol (R Coll Radiol). 2020 Oct;32(10):e211. doi: 10.1016/j.clon.2020.06.006. Epub 2020 Jul 11. Clin Oncol (R Coll Radiol). 2020. PMID: 32665103 Free PMC article. No abstract available.
2,040 results